Bioness today launched a patient registry for people using its StimRouter neuromodulation system for peripheral nerve stimulation.
Starting in the first quarter of 2019, patients will be able to opt into the StimRouter Registry, according to the Valencia, Calif.-based company.
Bioness’ StimRouter was launched in 2016 and the company touts it as the first neuromodulation product specifically designed to treat chronic peripheral nerve pain. The device has been implanted in more than 1,000 chronic pain patients across the U.S., according to Bioness.
“The StimRouter Registry is part of a comprehensive initiative to study and develop clinical data relative to peripheral nerve stimulation,” Bioness’ chief medical officer, Dr. Eric Grigsby, said in prepared remarks. “We strongly believe that PNS will play a critical role in the management of chronic pain of peripheral nerve origin.”
“As the first PNS product approved for commercial use, Bioness was very deliberate about the StimRouter launch to demonstrate safety and efficacy. The Registry is one more piece of our clinical study strategy to deliver robust, prospective clinical data to help define where PNS is best utilized and what we can learn to continue to launch new products that meet unmet medical needs in the neuromodulation market,” president & CEO Todd Cushman added.
Last year, Bioness reported the launch and first use of its StimRouter device in Canada.
